COVID-19 COVID-19
Conditions
Interventions
COVID-19 patients are randomly assigned (1:1) to either ensitrelvir or nirmatrelvir/ritonavir. Efficacy of the two medications are assessed.
Sponsors
Yoshimura Yukihiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.18 years old or more 2.Antigen or PCR test positive for SARS-CoV-2 3.0-3 days after symptom onset 4.Having risk factors of severe COVID-19 5.Written informed consent is obtained
Exclusion criteria
Exclusion criteria: 1.Severe adverse events by ensitrelvir or nirmatrelvir/ritonavir 2.Severe kidney failure (eGFR < 30 mL/min) 3.Taking contraindicated medications with ensitrelvir or nirmatrelvir/ritonavir 4.Regarded as inappropriate by study investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| five symptoms 5 or 6 days after starting medications | — |
Secondary
| Measure | Time frame |
|---|---|
| # 5 symptoms 28 to 30 days after starting medications # viral antigen titer 5 or 6 days after starting medications # unplanned visit of medical facilities or death # adverse events | — |
Contacts
Public ContactYukihiro Yoshimura
Yokohama Municipal Citizen's Hospital
Outcome results
None listed